drugset
drugset / Trial / NCT00109837

S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

NCT00109837 ↗

Phase 2 Completed 79 enrolled SWOG Cancer Research Network National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy), and giving the drugs in different combinations may kill more cancer cells. PURPOSE: This phase II trial is studying how well combination chemotherapy works in treating patients with newly diagnosed acute lymphoblastic leukemia.

Timeline

Start
2005-04
Primary completion
2010-11
Completion
2014-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclophosphamide Other / unclassified 650 mg/m2 Intravenous
Subject Cytarabine Small molecule 75 mg/m2 Intravenous
Subject Daunorubicin Small molecule 60 mg/m2 Intravenous
Subject Dexamethasone Small molecule 0.1 % Oral
Subject Dexamethasone Small molecule 10 mg/m2 Oral
Subject Doxorubicin Other / unclassified 25 mg/m2 Intravenous
Subject MERCAPTOPURINE ANHYDROUS Small molecule 60 mg/m2 Oral
Subject Methotrexate Small molecule 20 mg/m2 Intrathecal
Subject Mitoxantrone Small molecule 80 mg/m2 Intravenous
Subject Prednisone Other / unclassified 60 mg/m2 Oral
Subject Thioguanine Small molecule 60 mg/m2 Oral
Subject Vincristine Small molecule 1.4 mg/m2 Intravenous
Subject asparaginase Protein / enzyme biologic 2000 unknown Intramuscular
Background Allopurinol Small molecule 300 mg Oral
Background Leucovorin Small molecule 5 mg Oral
Background filgrastim Protein / enzyme biologic — Subcutaneous
Background trimethoprim-sulfamethoxazole Unknown — Oral

Indications

leukemia